Hacker News Reader

In theory then a bunch of pharma startups that have nailed their marketing costs should then flood the market with cheap new stuff. Why haven't they?

What incentive is there to do that? Is there anything preventing them from being gobbled up by current giants?

Being gobbled up at a premium is a reasonable exit strategy.

Well yea, but OP wondered where are these cheap drugs.